| Literature DB >> 21279390 |
Joanna Stefanowicz1, Mateusz Kosiak, Grzegorz Romanowicz, Radosław Owczuk, Elżbieta Adamkiewicz-Drożyńska, Anna Balcerska.
Abstract
Glomerular filtration rate (GFR) was evaluated in 32 Wilms' tumour survivors (WTs) in a cross-sectional study using 99 Tc-diethylene triamine pentaacetic acid (99 Tc-DTPA) clearance, the Schwartz formula, the new Schwartz equation for chronic kidney disease (CKD), cystatin C serum concentration and the Filler formula. Kidney damage was established by beta-2-microglobulin (B-2-M) and albumin urine excretion, urine sediment and ultrasound examination. Blood pressure was measured. No differences were found between the mean GFR in 99 Tc-DTPA and the new Schwartz equation for CKD (91.8 ± 11.3 vs. 94.3 ± 10.2 ml/min/1.73 m(2) [p = 0.55] respectively). No differences were observed between estimated glomerular filtration rate (eGFR) using the Schwartz formula and the Filler formula either (122.3 ± 19.9 vs. 129.8 ± 23.9 ml/min/1.73 m(2) [p = 0.28] respectively). Increased urine albumin and B-2-M excretion, which are signs of kidney damage, were found in 7 (22%) and 3 (9.4%) WTs respectively. Ultrasound signs of kidney damage were found in 14 patients (43%). Five patients (15.6%) had more than one sign of kidney damage. Eighteen individuals (56.25%) had CKD stage I (10 with signs of kidney damage; 8 without). Fourteen individuals (43.75%) had CKD stage II (6 with signs of kidney damage; 8 without). The new Schwartz equation for CKD better estimated GFR in comparison to the Schwartz formula and the Filler formula. Furthermore, the WT survivors had signs of kidney damage despite the fact that GFR was not decreased below 90 ml/min/1.73 m(2) with 99 Tc- DTPA.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21279390 PMCID: PMC3062777 DOI: 10.1007/s00467-011-1759-3
Source DB: PubMed Journal: Pediatr Nephrol ISSN: 0931-041X Impact factor: 3.714
Characteristics of the patients enrolled in the study
| Mean | Standard deviation | Median | Range | |
|---|---|---|---|---|
| Age (years) | 13 | 5.4 | 12.2 | 3.6–24.3 |
| Time of follow-up (years) | 9.3 | 5.4 | 7.75 | 0.3–20.6 |
| Weight (kg) | 43.9 | 16.8 | 42.8 | 21.7–77.4 |
| Height (cm) | 152.5 | 20.7 | 154 | 110–184.5 |
| BMI (kg/m2] | 18 | 3 | 17.5 | 13.4–24.4 |
| Age at time of diagnosis (years) | 8.52 | 5.7 | 2.9 | 0.08–11.4 |
BMI, body mass index
Characteristics of the individuals who received potentially nephrotoxic agents (patients 1–7) and underwent radiation of the solitary kidney (patients 6–8)
| CHT | RTX | GFR 99 Tc-DTPA (ml/min/1.73m2) | Albumin urine concentration (mg/L) | ACR (mg/g) | B-2-M (mg/dl) | BCR (mg/mol) | Ultrasound | Duration of follow-up (years) | Age at time of diagnosis (years) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Yes | Yes: bed of removed kidney | 102 | 20.9 | 15.9 | 0.17 | 0.01 | No abnormality | 11.8 | 6.2 |
| 2 | Yes | No | 87 | 3.1 | 13.9 | 0.02 | 0.01 | No abnormality | 3.4 | 4 |
| 3 | Yes | No | 75 | 40.6 | 69.5 | 7.8 | 1.51 | No abnormality | 5.3 | 7.4 |
| 4 | Yes | Yes: bed of removed kidney | 68 | 7.2 | 43.6 | 0.66 | 0.45 | Increased echogenicity of the renal cortex | 9 | 2.3 |
| 5 | Yes | Yes: bed of removed kidney | 114 | 2.3 | 5.1 | 0.29 | 0.07 | Increased echogenicity of the renal cortex | 20.6 | 0.9 |
| 6 | Yes | Total abdomen | 105 | 9.5 | 7.1 | 0.09 | 0.01 | Increased echogenicity of the renal cortex + a simple renal cyst | 16 | 2.3 |
| 7 | Yes | Total abdomen | 71 | 2.2 | 10.7 | 0.11 | 0.06 | Hyperechogenic rings around renal pyramids | 15.4 | 4 |
| 8 | No | Total abdomen | 100 | 17.3 | 17.1 | 0.09 | 0.01 | Hyperechogenic rings around renal pyramids | 3.9 | 7.5 |
Shaded area represents Wilms’ tumour survivors who underwent irradiation of the solitary kidney
ACR, urine albumin to creatinine ratio; B-2-M, beta-2-microglobulin urine concentration; BCR, a urine beta-2-microglobulin to creatinine ratio; CHT, chemotherapy; GFR, glomerular filtration rate; RTX, radiotherapy; 99 Tc-DTPA, 99 Tc-diethylene triamine pentaacetic acid
Mean values of GFR and standard deviation (SD) assessed with different methods and the mean value and the SD of cystatin C serum concentration
| Mean GFR (ml/min/1.73 m2) | SD | |
|---|---|---|
| GFR 99 Tc-DTPA | 94.28 | 10.24 |
| eGFR Schwartz | 122.26 | 19.92 |
| eGFR new Schwartz equation for children with CKD | 94.26 | 10.22 |
| Cystatin C | 0.76 | 0.12 |
| eGFR Filler | 129.83 | 23.89 |
GFR, glomerular filtration rate; eGFR, estimated glomerular filtration rate; 99 Tc-DTPA, 99 Tc-diethylene triamine pentaacetic acid; CKD, chronic kidney disease
Number of patients with a decreased GFR
| Number of patients with decreased GFR (<90 ml/min/1.73 m2); | |
|---|---|
| GFR 99Tc-DTPA | 14 (43.8%) |
| eGFR Schwartz | 1 (3.1%) |
| eGFR new Schwartz equation for children with CKD | 11 (34.4%) |
| eGFR Filler | 0 |
CKD chronic kidney disease
Prevalence of signs of kidney damage in ultrasound examination
| Sign of kidney damage in ultrasound examination | Number of patients |
|---|---|
| Hyperechoic rings around renal pyramids | 12 |
| Renal scars | 3 |
| Echogenicity of renal cortex | 5 |
| Urolithiasis | 0 |
| Cysts | 1 |
Prevalence of CKD in Wilms’ tumour survivors
| Number of patients | ||
|---|---|---|
| CKD stage I | GFR > 90 ml/min/1.73 m2 no signs of kidney damage | 8 |
| GFR > 90 ml/min/1.73 m2 + signs of kidney damage | 10 | |
| CKD stage II | GFR 60–89 ml/min/1.73 m2 no signs of kidney damage | 8 |
| GFR 60–89 ml/min/1.73 m2 + signs of kidney damage | 6 |